Journal of clinical lipidology最新文献

{"title":"Implementation of guideline-based lipid reporting and rate of lipid lowering therapy prescription.","authors":"Anish Adhikari, Aya Haghamad, Xueqi Huang, Joanna Fishbein, Georgeta Vaidean, Jamie S Hirsch, James M Crawford, Maya Rubin, Monique Carrero-Tagle, Eugenia Gianos","doi":"10.1016/j.jacl.2024.12.012","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.012","url":null,"abstract":"<p><p>Lipid goal attainment remains suboptimal due to patient, provider, and system level factors. We aimed to assess whether updated, guideline-based lipid reporting and clinical decision support was associated with different lipid-lowering therapy (LLT) prescription patterns. We conducted a retrospective study in our electronic health record (EHR) comparing prescriptions within 90 days of lab reporting both prior to the reporting change (21,417 patients in 2019-2020) and after (39,866 patients in 2020-2021). We found a significant increase in the initiation of LLT in patients > 40 years of age with LDL-C ≥ 100  mg/dL, with 2377 (11.6%) initiated prior to compared to 6205 (16.3%) after the reporting change (P < .001). Among 4469 adult patients with ASCVD and LDL-C ≥ 70 mg/dL prior to (n = 2040) and after (n = 3277) the reporting change, there was a significantly higher rate of LLT initiation, 444 (25.9%) prior to vs 875 (31.8%) after; P < .001. In conclusion, after implementation of updated guideline-based lipid test reporting, we observed higher initiation rates of LLT for indicated patients. Our study suggests that guideline-based reporting of lipid test results may aid in guideline implementation.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe-associated rhabdomyolysis: A comprehensive assessment of the USFDA adverse event reporting system using disproportionality analysis, case reviews and meta-analysis of randomized clinical trials.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan","doi":"10.1016/j.jacl.2024.12.010","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.010","url":null,"abstract":"<p><strong>Background: </strong>Ezetimibe, a Niemann-Pick C1-like 1 inhibitor, is widely prescribed as a monotherapy or in combination with statins to reduce cholesterol levels. Although generally well-tolerated, concerns have emerged regarding the risk of rhabdomyolysis, particularly with combination therapies. This study aims to evaluate the association between ezetimibe and rhabdomyolysis using data from the United States Food and Drug Administration's Adverse Event Reporting System (USFDA AERS), case reviews, and a meta-analysis of clinical trials.</p><p><strong>Methods: </strong>We analyzed reports from the USFDA AERS between Q1 2004 and Q2 2024, focusing on cases with rhabdomyolysis with ezetimibe alone or in combination with statins or bempedoic acid. Disproportionality analysis using both frequentist and Bayesian methods was conducted. We also reviewed published case reports and performed a meta-analysis of randomized clinical trials comparing ezetimibe monotherapy with placebo.</p><p><strong>Results: </strong>Of 29,153,222 reports in AERS, 668 cases met the inclusion criteria. Frequentist and Bayesian analyses indicated an increased risk of rhabdomyolysis with ezetimibe alone and with statin combinations, particularly with simvastatin and atorvastatin. Interaction signal scores suggested statistically significant interactions between ezetimibe and certain statins (atorvastatin and rosuvastatin). Case reviews identified nine published cases, most of which involved ezetimibe in patients on a stable background therapy of statins. The meta-analysis of 3 trials did not show a significant risk for rhabdomyolysis with ezetimibe monotherapy.</p><p><strong>Conclusion: </strong>This study suggests a potentially possible association between ezetimibe (monotherapy and in combination), and rhabdomyolysis risk. Clinicians should monitor patients closely, particularly those on combination therapies. Further prospective studies are needed to elucidate causality and inform safe prescribing practices.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel variant in the ABCA1 gene for Tangier Disease with diffuse histiocytosis of bone marrow.","authors":"Ana Rita Ramalho, Sónia Moreira, Lina C Ramos, José Pereira de Moura","doi":"10.1016/j.jacl.2024.12.008","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.008","url":null,"abstract":"<p><p>Tangier disease is an extremely rare autosomal recessive monogenic disorder caused by mutations in the ATP binding cassette transporter A1 gene (ABCA1). It is characterized by severe deficiency or absence of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-1 (ApoA1), with highly variable clinical presentations depending on cholesterol accumulation in macrophages across different tissues. We report a case of a 47-year-old man with very low HDL-C and very high triglyceride levels, initially attributed to the patient's metabolic syndrome, alcohol abuse, and splenomegaly. He had pancytopenia and splenomegaly for over fourteen years and developed premature myocardial infarction during his diagnostic workup. Suspecting of Tangier disease, we sequenced the ABCA1 gene, which revealed a homozygous new variant c.164A>G p (His5Arg) in the exon 4. Given the limited number of published cases, there are no reliable data on genotype-phenotype correlations in Tangier disease, highlighting the importance of reporting new variants and associated clinical features.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential coronary heart disease risk among antihypertensive and lipid-lowering medication users versus non-users: A real-world data analysis.","authors":"Michihiro Satoh, Shingo Nakayama, Hideaki Hashimoto, Maya Toyama, Yutaro Iwabe, Takahito Yagihashi, Takahisa Murakami, Taku Obara, Takayoshi Ohkubo, Hirohito Metoki","doi":"10.1016/j.jacl.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.006","url":null,"abstract":"<p><strong>Background: </strong>We aimed to precisely quantify the risk of coronary heart disease (CHD) among antihypertensive medication users compared to non-users. We similarly assessed the potential CHD risk among lipid-lowering medication users.</p><p><strong>Methods: </strong>This retrospective cohort study used claims and health checkup data from 2014 to 2021 provided by DeSC Healthcare, Inc. We used percutaneous coronary intervention (PCI) risk as a proxy for the CHD outcome.</p><p><strong>Results: </strong>Among the 1,740,153 participants without a history of cardiovascular and kidney diseases, 3803 underwent PCI during a mean follow-up of 3.2 years. The Cox model with health insurers as the stratified factor showed that blood pressure (BP) classification according to the hypertension guidelines was linearly associated with PCI risk. In contrast, this association was weaker in antihypertensive medication users than in nonusers. After restricting to 1,309,460 participants with BP <140/<90 mm Hg, the antihypertensive medication users had a 1.51 (95% CI: 1.37-1.66) times higher PCI risk than nonusers even after adjusting for baseline characteristics including systolic BP. This was consistent in all subgroups stratified by characteristics including body mass index, drinking status, diabetes, systolic BP, and follow-up years. Meanwhile, the use of lipid-lowering medications was not associated with PCI risk (HR: 0.98, 95% CI: 0.88-1.09 in 1,221,390 patients with low-density lipoprotein cholesterol <3.62 mmol/L [<140 mg/dL]).</p><p><strong>Conclusions: </strong>Especially for hypertension, it is important not only to lower BP with medication but also to avoid the need for medication through early prevention and lifestyle changes.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the impact of insurance switching on the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers.","authors":"Lauren E Hendy, Lisa P Spees, Casey Tak, Delesha M Carpenter, Kathleen C Thomas, Megan C Roberts","doi":"10.1016/j.jacl.2024.12.003","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.003","url":null,"abstract":"<p><strong>Background: </strong>Widespread familial hypercholesterolemia screening requires a large upfront economic investment, but the health benefits and cost savings of cardiovascular disease prevention directed by screening occur over many years.</p><p><strong>Objective: </strong>We evaluated the cost-effectiveness of population genetic screening for familial hypercholesterolemia compared to cascade testing to US payers while accounting for patient insurance switching between commercial and Medicare insurance.</p><p><strong>Methods: </strong>We developed a hybrid decision-tree Markov model to assess genetic screening in 20-year-old adults over a lifetime horizon in which cohort members transitioned between commercial payers representing three commercial plans and Medicare. Health state and coverage transition probabilities, utilities, and event costs were primarily sourced from published literature. We estimated incremental cost-effectiveness ratios per quality-adjusted life year gained and conducted probabilistic and one-way sensitivity analyses to explore parameters.</p><p><strong>Results: </strong>Population genetic screening cost an additional $1,024,126, $495,909, and $479,170 per quality-adjusted life year gained for the high, medium, and low benefit commercial payers. Medicare experienced both cost savings and greater quality-adjusted life years in its members under population genetic screening.</p><p><strong>Conclusions: </strong>Insurance switching substantially affects the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers. Future research examining screening and treatments for other rare diseases that require high investment early in life for downstream health benefits should consider the impact of insurance switching in the US.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cumulative exposure to a high TG to HDL-C ratio on type 2 diabetes risk in young adults.","authors":"Jung Heo, Byungpyo Kim, Kyungdo Han, Jae-Hyuk Lee, Seo-Young Sohn, Jiyeon Ahn, Whi-An Kwon, Moon Jung Kim, Eun-Young Doo, Min-Kyung Lee","doi":"10.1016/j.jacl.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.12.004","url":null,"abstract":"<p><strong>Background: </strong>Increases in the prevalence of type 2 diabetes (T2D) pose significant challenges to its prediction and prevention.</p><p><strong>Objective: </strong>We aimed to evaluate whether cumulative exposure to a high triglyceride to high-density lipoprotein-cholesterol (TG/HDL-C) ratio is associated with increased T2D risk in young adults.</p><p><strong>Methods: </strong>We collected South Korean National Health Insurance Service data between 2009 and 2012 from 1,840,251 young adults without T2D aged 20 to 39 years who underwent 4 consecutive annual health checkups. Participants were classified into 5 groups based on exposure to a high TG/HDL-C ratio, defined as the highest TG/HDL-C ratio quartile. T2D risk was evaluated using a multivariate Cox proportional hazard model.</p><p><strong>Results: </strong>During the 6.53-year follow-up period, 40,286 participants (2.2%) developed T2D. The cumulative incidence of T2D increased with higher TG/HDL-C exposure scores. The adjusted hazard ratios of TG/HDL-C ratio exposure scores for T2D were 1.584 (95% confidence interval (CI), 1.488-1.686), 2.101 (95% CI, 1.980-2.228), 2.942 (95% CI, 2.787-3.106), and 4.962 (95% CI, 4.718-5.219) for groups with scores of 1 to 4, respectively, compared with those with a score of 0. Further subgroup analyses stratified by age, sex, and statin use revealed no significant differences in risk of T2D.</p><p><strong>Conclusion: </strong>Cumulative exposure to high TG/HDL-C ratio was associated with increased risk of T2D in young Korean adults, suggesting its importance in prediction and prevention. Subgroup analysis revealed no significant differences in age, sex, or statin use. Further research is required to explore the underlying mechanisms and develop effective interventions.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated stearoyl-CoA desaturase activity mediates the associations of total cysteine with adiposity: The Maastricht Study.","authors":"Elena C Tore, Bregje C Adriaans, Thomas Olsen, Kathrine J Vinknes, M Eline Kooi, Amany K Elshorbagy, Nasser E Bastani, Pieter C Dagnelie, Simone J P M Eussen, Thomas E Gundersen, Viktor Kožich, Helga Refsum, Kjetil Retterstøl, Emma T K Stolt, Marleen M J van Greevenbroek","doi":"10.1016/j.jacl.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.11.005","url":null,"abstract":"<p><strong>Background: </strong>Plasma sulfur amino acids (SAAs), particularly cysteine, are associated with obesity. One proposed mechanism is the altered regulation of the stearoyl-CoA desaturase (SCD) enzyme. Changes in the SCD enzyme activity have been linked to obesity, as well as to plasma SAA concentrations.</p><p><strong>Objective: </strong>This study aimed to investigate whether estimated SCD activity mediates the associations between plasma SAAs and measures of overall adiposity and specific fat depots.</p><p><strong>Methods: </strong>We examined cross-sectional data from a subset of the Maastricht Study (n = 1129, 50.7% men, 56.7% with (pre)diabetes). Concentrations of methionine, total homocysteine, cystathionine, total cysteine (tCys), total glutathione (tGSH) and taurine were measured in fasting plasma. Outcomes included measures of overall, peripheral and central adiposity, and liver fat. SCD activity was estimated by ratios of serum fatty acids as SCD16 and SCD18 indices. The associations between plasma SAAs and measures of adiposity or liver fat were examined with multiple linear regression analysis. Multiple mediation analysis was used to investigate whether the significant associations were mediated by SCD16 and SCD18 indices.</p><p><strong>Results: </strong>Plasma tCys was positively associated with all adiposity measures (β ranged from 0.15 to 0.30). SCD16 significantly mediated all associations (proportion mediated ranged from 5.1% to 9.7%). Inconsistent mediation effects were found for SCD18. Despite a significant inverse association of plasma tGSH with all adiposity measures (β ranged from -0.08 to -0.16), no significant mediation effect was found.</p><p><strong>Conclusions: </strong>Plasma tCys may promote excessive body fat accumulation via upregulation of SCD activity.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe in the management of homozygous familial hypercholesterolaemia.","authors":"Brett S Mansfield, Adriano Dello-Iacono, Frederick J Raal","doi":"10.1016/j.jacl.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Homozygous familial hypercholesterolaemia (HoFH) is a severe lipid disorder leading to accelerated atherosclerotic cardiovascular disease (ASCVD). This study aimed to evaluate the efficacy of ezetimibe, a cholesterol absorption inhibitor, in reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with genetically confirmed HoFH.</p><p><strong>Methods: </strong>This retrospective review included 48 individuals with genetically confirmed HoFH attending the Lipid Clinic at an Academic Hospital in Johannesburg, South Africa. All patients were on stable high-intensity statin therapy for at least 6 months before starting ezetimibe 10 mg orally daily. Lipid profiles at baseline and after 3 and 6 months of ezetimibe therapy were documented. Responders (LDL-C reduction ≥20%) were compared to nonresponders (LDL-C reduction <20%).</p><p><strong>Results: </strong>Ezetimibe led to a 19.1% further reduction in LDL-C at 6 months. Among the participants, 23 were considered responders and 25 were nonresponders. Responders showed a 26.4% LDL-C reduction at 3 months and 31.6% at 6 months, compared to nonresponders with 8.5% and 5.9% reductions in LDL-C respectively. Individuals with the null LDL receptor variant c.1285G>A (p.Val429Met) were less likely to respond. However, response to ezetimibe was highly variable across all pathogenic variants.</p><p><strong>Conclusion: </strong>Ezetimibe, in combination with high-intensity statin therapy, significantly reduces LDL-C levels in patients with genotypically confirmed HoFH. However, the response to ezetimibe is highly variable and unpredictable across genotypes. This study supports the inclusion of ezetimibe in the treatment regimen for all HoFH patients to reduce the risk of ASCVD. Further studies are needed to understand the variable responses to ezetimibe among different genotypes and in HoFH individuals with the same genotype.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidology: The time is now for specialty recognition.","authors":"Kaye-Eileen Willard, Don P Wilson, Elizabeth J Jackson, Carol F Kirkpatrick, Mary Katherine Cheeley, Dinesh K Kalra","doi":"10.1016/j.jacl.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.11.002","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome.","authors":"Shimpei Fujioka, Daisuke Shishikura, Hirofumi Kusumoto, Yohei Yamauchi, Kazushi Sakane, Tomohiro Fujisaka, Kensaku Shibata, Hideaki Morita, Yumiko Kanzaki, Masahito Michikura, Mariko Harada-Shiba, Masaaki Hoshiga","doi":"10.1016/j.jacl.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.10.010","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines advocate achieving a fixed LDL-C target and ≥50% reduction in LDL-C levels. However, sufficient LDL-C reduction is often not achieved even in patients achieving a fixed LDL-C target.</p><p><strong>Objective: </strong>This study investigated the clinical impact of insufficient LDL-C reduction following lipid lowering therapy on cardiovascular outcomes acute coronary syndrome (ACS) patients.</p><p><strong>Methods: </strong>A total of 561 consecutive ACS patients who had undergone PCI and LDL-C level measurement at index PCI and 12 months afterwards were evaluated retrospectively. we investigated a relationship between ≥50% LDL-C reduction and cardiovascular events including the composite of cardiac death, myocardial infarction, target vessel revascularization and stent thrombosis.</p><p><strong>Results: </strong>Of the patients, 145 (25.8%) achieved ≥50% LDL-C reduction within 12 months. There were no significant differences in cardiovascular events between patients achieving the LDL-C target of 55 mg/dL and those not achieving it (23.6% vs 19.3%, P = .77), whereas the incidence of cardiovascular events was higher in the <50% LDL-C reduction group than the ≥50% LDL-C reduction group (26.0% vs 12.4%, P = .009). Even in patients with LDL-C < 55 mg/d/L, cardiovascular events were more frequently in the <50% LDL-C reduction group than the ≥50% LDL-C reduction group (28.8% vs 13.2%, P = .04). Cox proportional hazard models revealed that <50% LDL-C reduction was an independent predictor of cardiovascular outcomes (HR: 2.03, 95% CI: 1.23-3.36).</p><p><strong>Conclusion: </strong>The current study underscores the significance of achieving ≥50% LDL-C reduction in addition to a target of 55 mg/dL in preventing additional cardiovascular events in ACS patients.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}